No Prescription |
 |
 | ||
|
Diamicron MR Generic Gliclazide |
|
| ||
No Prescription » Prescription Drugs 6 » Diamicron MR Generic Gliclazide Diamicron is used to control the blood sugar in patients with Type 2 Diabetes / Non insulin dependent diabetes mellitus when the diet exercise and weight loss have failed to fully control blood sugar. Buy Diamicron MR Generic Gliclazide and other Prescription Drugs 6 products online at Medstore. Buy Online at Medstore - Click Here!
About Diamicron MR Generic Gliclazide: Product Type: Prescription Drugs 6 Diamicron MR ( Generic Gliclazide ) Diamicron MR (Generic Gliclazide) Generic Gliclazide 30mg 30 Tablets 30mg 90 Tablets 30mg 180 Tablets 30mg 400(4 x 100 Tablets) 30mg 100 Tablets 30mg 200(2 x 100 Tablets) Generic Gliclazide Diamicron MR
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
